Skip to main content

Table 4 Pronostic factors of overall survival (Cox model)

From: Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France

 

Univariate analysis

 

Multivariate analysis

 
 

HR

p

HR

p

Gleason score

4-6

1

   

7

1.54 95% CI [0.91-2.60]

0.11

8-10

1.63 95% CI [0.98-2.72]

0.06

Nb CT line

1

1

   

2

1.17 95% CI [0.86-1.60]

0.309

3

1.09 95% CI [0.59-2.03]

0.785

4

1.11 95% CI [0.52-2.39]

0.788

5

0.81 95% CI [0.11-5.82]

0.835

Sites of metastasis

Bone or visceral alone vs Multiple

1

0.025

1

0.019

1.38

 

1.41

95% CI [1.04-1.83]

 

95% CI [1.05-1.88]

Previous hormonal treatment duration

Less than 70 months vs More than 70 months

1

0.001

1

0.001

0.55

 

0.54

 

95% CI [0.39-0.79]

 

95% CI [0.38-0.77]

Duration of AA treatment

Less than 3 months vs More than 3 months

1

<0.001

1

<0.001

0.52

 

0.55

 

95% CI [0.38-0.74]

 

95% CI [0.39-0.77]